Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma

Sami Al-Nadaf, Robert B Rebhun, Kaitlin M. Curran, Rachel O. Venable, Katherine A Skorupski, Jennifer Willcox, Jenna H Burton

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: A doxorubicin (DOX)-based chemotherapy protocol, CHOP, is the most effective treatment for canine high-grade B-cell lymphoma; however, the cost and time requirements associated with this protocol are not feasible for many pet owners. An alternative treatment option is the use of DOX, the most effective drug, in combination with prednisone. Prior studies with single-agent DOX included dogs with T-cell lymphoma, a known negative prognostic factor, which may have resulted in shorter reported survival times than if dogs with B-cell lymphoma were analyzed separately. The purpose of this study was to evaluate the outcome of dogs with high-grade B-cell lymphoma when treated with DOX and prednisone with or without L-asparaginase (L-ASP). Identification of prognostic factors was of secondary interest. RESULTS: Thirty-three dogs were included in the study; 31 dogs were evaluable for response with an overall response rate of 84%. The median progression free survival (PFS) and overall survival (OS) were 147 days and 182 days, respectively. The one-year survival fraction was 23%. No variable other than protocol completion was found to be significant for either PFS or OS including historical prognostic factors such as substage, thrombocytopenia, and body weight. CONCLUSIONS: Dogs with high-grade B-cell lymphoma treated with DOX and prednisone with or without L-ASP have similar response rates, PFS, and OS to prior studies that did not differentiate between lymphoma immunophenotype. This protocol is not a replacement for CHOP; however, it is an alternative if time and cost are factors, while providing therapeutic benefit greater than prednisone alone.

Original languageEnglish (US)
Number of pages1
JournalBMC Veterinary Research
Volume14
Issue number1
DOIs
StatePublished - Nov 20 2018

Fingerprint

prednisone
doxorubicin
B-Cell Lymphoma
Prednisone
lymphoma
Doxorubicin
B-lymphocytes
Canidae
Dogs
therapeutics
dogs
Non-Hodgkin's Lymphoma
Disease-Free Survival
Asparaginase
asparaginase
Therapeutics
Costs and Cost Analysis
T-Cell Lymphoma
Pets
combination drug therapy

Keywords

  • Adriamycin
  • Cancer
  • Canine
  • Chemotherapy
  • Immunophenotype

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma. / Al-Nadaf, Sami; Rebhun, Robert B; Curran, Kaitlin M.; Venable, Rachel O.; Skorupski, Katherine A; Willcox, Jennifer; Burton, Jenna H.

In: BMC Veterinary Research, Vol. 14, No. 1, 20.11.2018.

Research output: Contribution to journalArticle

@article{87082ffb72d3406f8693f7b533516141,
title = "Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma",
abstract = "BACKGROUND: A doxorubicin (DOX)-based chemotherapy protocol, CHOP, is the most effective treatment for canine high-grade B-cell lymphoma; however, the cost and time requirements associated with this protocol are not feasible for many pet owners. An alternative treatment option is the use of DOX, the most effective drug, in combination with prednisone. Prior studies with single-agent DOX included dogs with T-cell lymphoma, a known negative prognostic factor, which may have resulted in shorter reported survival times than if dogs with B-cell lymphoma were analyzed separately. The purpose of this study was to evaluate the outcome of dogs with high-grade B-cell lymphoma when treated with DOX and prednisone with or without L-asparaginase (L-ASP). Identification of prognostic factors was of secondary interest. RESULTS: Thirty-three dogs were included in the study; 31 dogs were evaluable for response with an overall response rate of 84{\%}. The median progression free survival (PFS) and overall survival (OS) were 147 days and 182 days, respectively. The one-year survival fraction was 23{\%}. No variable other than protocol completion was found to be significant for either PFS or OS including historical prognostic factors such as substage, thrombocytopenia, and body weight. CONCLUSIONS: Dogs with high-grade B-cell lymphoma treated with DOX and prednisone with or without L-ASP have similar response rates, PFS, and OS to prior studies that did not differentiate between lymphoma immunophenotype. This protocol is not a replacement for CHOP; however, it is an alternative if time and cost are factors, while providing therapeutic benefit greater than prednisone alone.",
keywords = "Adriamycin, Cancer, Canine, Chemotherapy, Immunophenotype",
author = "Sami Al-Nadaf and Rebhun, {Robert B} and Curran, {Kaitlin M.} and Venable, {Rachel O.} and Skorupski, {Katherine A} and Jennifer Willcox and Burton, {Jenna H}",
year = "2018",
month = "11",
day = "20",
doi = "10.1186/s12917-018-1688-5",
language = "English (US)",
volume = "14",
journal = "BMC Veterinary Research",
issn = "1746-6148",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma

AU - Al-Nadaf, Sami

AU - Rebhun, Robert B

AU - Curran, Kaitlin M.

AU - Venable, Rachel O.

AU - Skorupski, Katherine A

AU - Willcox, Jennifer

AU - Burton, Jenna H

PY - 2018/11/20

Y1 - 2018/11/20

N2 - BACKGROUND: A doxorubicin (DOX)-based chemotherapy protocol, CHOP, is the most effective treatment for canine high-grade B-cell lymphoma; however, the cost and time requirements associated with this protocol are not feasible for many pet owners. An alternative treatment option is the use of DOX, the most effective drug, in combination with prednisone. Prior studies with single-agent DOX included dogs with T-cell lymphoma, a known negative prognostic factor, which may have resulted in shorter reported survival times than if dogs with B-cell lymphoma were analyzed separately. The purpose of this study was to evaluate the outcome of dogs with high-grade B-cell lymphoma when treated with DOX and prednisone with or without L-asparaginase (L-ASP). Identification of prognostic factors was of secondary interest. RESULTS: Thirty-three dogs were included in the study; 31 dogs were evaluable for response with an overall response rate of 84%. The median progression free survival (PFS) and overall survival (OS) were 147 days and 182 days, respectively. The one-year survival fraction was 23%. No variable other than protocol completion was found to be significant for either PFS or OS including historical prognostic factors such as substage, thrombocytopenia, and body weight. CONCLUSIONS: Dogs with high-grade B-cell lymphoma treated with DOX and prednisone with or without L-ASP have similar response rates, PFS, and OS to prior studies that did not differentiate between lymphoma immunophenotype. This protocol is not a replacement for CHOP; however, it is an alternative if time and cost are factors, while providing therapeutic benefit greater than prednisone alone.

AB - BACKGROUND: A doxorubicin (DOX)-based chemotherapy protocol, CHOP, is the most effective treatment for canine high-grade B-cell lymphoma; however, the cost and time requirements associated with this protocol are not feasible for many pet owners. An alternative treatment option is the use of DOX, the most effective drug, in combination with prednisone. Prior studies with single-agent DOX included dogs with T-cell lymphoma, a known negative prognostic factor, which may have resulted in shorter reported survival times than if dogs with B-cell lymphoma were analyzed separately. The purpose of this study was to evaluate the outcome of dogs with high-grade B-cell lymphoma when treated with DOX and prednisone with or without L-asparaginase (L-ASP). Identification of prognostic factors was of secondary interest. RESULTS: Thirty-three dogs were included in the study; 31 dogs were evaluable for response with an overall response rate of 84%. The median progression free survival (PFS) and overall survival (OS) were 147 days and 182 days, respectively. The one-year survival fraction was 23%. No variable other than protocol completion was found to be significant for either PFS or OS including historical prognostic factors such as substage, thrombocytopenia, and body weight. CONCLUSIONS: Dogs with high-grade B-cell lymphoma treated with DOX and prednisone with or without L-ASP have similar response rates, PFS, and OS to prior studies that did not differentiate between lymphoma immunophenotype. This protocol is not a replacement for CHOP; however, it is an alternative if time and cost are factors, while providing therapeutic benefit greater than prednisone alone.

KW - Adriamycin

KW - Cancer

KW - Canine

KW - Chemotherapy

KW - Immunophenotype

UR - http://www.scopus.com/inward/record.url?scp=85056803855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056803855&partnerID=8YFLogxK

U2 - 10.1186/s12917-018-1688-5

DO - 10.1186/s12917-018-1688-5

M3 - Article

C2 - 30458771

AN - SCOPUS:85056803855

VL - 14

JO - BMC Veterinary Research

JF - BMC Veterinary Research

SN - 1746-6148

IS - 1

ER -